Biological
AGS-004
AGS-004 is a biological therapy with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_1
Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
NCT02707900
completedphase_1
A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004
NCT02042248
completedphase_2
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
NCT01069809
completedphase_2
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
NCT00672191
completedphase_1
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
NCT00381212
Clinical Trials (5)
Showing 5 of 5 trials
NCT02707900Phase 1
Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
NCT02042248Phase 1
A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004
NCT01069809Phase 2
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
NCT00672191Phase 2
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
NCT00381212Phase 1
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5